SEARCH

SEARCH BY CITATION

References

  • 1
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S59S.
  • 2
    Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 2009; 139: 43852.
  • 3
    Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2006; 118: 41722.
  • 4
    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 67384.
  • 5
    Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15: 3192206.
  • 6
    Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007; 11: 17889.
  • 7
    Schrader J, Tonnis HJ, Scheler F. Long-term intraperitoneal application of low molecular weight heparin in a continuous ambulatory peritoneal dialysis patient with deep vein thrombosis. Nephron 1986; 42: 834.
  • 8
    Kleta R, Frund S, Kuwertz-Broking E, Bulla M. Intraperitoneal application of low-molecular-weight heparin in continuous ambulatory peritoneal dialysis in a child. Nephron 2000; 86: 545.
  • 9
    Sifil A, Mermut C, Yenicerioglu Y, Cavdar C, Gumustekin M, Celik A, Yuksel F, Camsari T. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19: 2830.
  • 10
    Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol 2006; 46: 88794.
  • 11
    Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost 2009; 7: 5528.
  • 12
    Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 22531.